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Abstract
Background: Single-incision laparoscopic surgery (SILS) is an emerging minimally invasive surgery to reduce
abdominal incisions. However, despite the increasing clinical application of SILS, no evidence from large-scale,
randomized controlled trials is available for assessing the feasibility, short-term safety, oncological safety, and
potential benefits of SILS compared with conventional laparoscopic surgery (CLS) for colorectal cancer.
Methods/Design: This is a single-center, open-label, noninferiority, randomized controlled trial. A total of 198
eligible patients will be randomly assigned to transumbilical single incision plus one port laparoscopic surgery (SILS
plus one) group or to a CLS group at a 1:1 ratio. Patients ranging in age from 18 to 80 years with rectosigmoid
cancer diagnosed as cT1-4aN0-2 M0 and a tumor size no larger than 5 cm are considered eligible. The primary
endpoint is early morbidity, as evaluated by an independent investigator. Secondary outcomes include operative
outcomes (operative time, estimated blood loss, and incision length), pathologic outcomes (tumor size, length of
proximal and distal resection margins, and number of harvested lymph nodes), postoperative inflammatory and
immune responses (white blood cells [WBC], neutrophil percentage [NE %], C-reactive protein [CRP], interleukin-6
[IL-6], and tumor necrosis factor-α [TNF-α]), postoperative recovery (time to first ambulation, flatus, liquid diet, soft
diet, and duration of hospital stay), pain intensity, body image and cosmetic assessment, 3-year disease free survival
(DFS), and 5-year overall survival (OS). Follow-up visits are scheduled for 1 and 3 months after surgery, then every
3 months for the first 2 years and every 6 months for the next 3 years.
Discussion: This trial will provide valuable clinical evidence for the objective assessment of the feasibility, safety,
and potential benefits of SILS plus one compared with CLS for the radical resection of rectosigmoid cancer. The
hypothesis is that SILS plus one is feasible for the radical resection of rectosigmoid cancer and offers short-term
safety and long-term oncological safety comparable to that of CLS, and that SILS plus one offers better cosmetic
results and faster convalescence compared to CLS.
Trial registration: ClinicalTrials.gov: NCT02117557 (registered on 16 April 2014).
Keywords: Colorectal cancer, laparoscopy, single incision, SILS, rectosigmoid, transumbilical, randomized controlled
trial, study protocol
* Correspondence: navyd999@163.com; gzliguoxin@163.com
Yanan Wang and Ruoyan Liu are co-first authors.
†Equal contributors
1Department of General Surgery, Nanfang Hospital, Southern Medical
University, North Guangzhou Road 1838, 510-515 Guangzhou, China
Full list of author information is available at the end of the article
© 2015 Wang et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.




Colorectal cancer is one of the most commonly diag-
nosed cancers worldwide, and adequate surgical excision
of the primary tumor is the only curative treatment [1,
2]. As the minimally invasive surgical era evolves and
laparoscopic techniques continue to develop, conven-
tional laparoscopic surgery (CLS) has been recom-
mended as an alternative to open surgery for colorectal
cancer. Compared with open surgery, CLS provides
various advantages, including reduced pain, a shorter
hospital stay, and improved cosmetic results [3–6].
Furthermore, many studies have demonstrated that its
short-term safety and long-term oncological safety, in
terms of DFS and OS, are comparable to those of open
surgery [3–9]. These excellent results have encouraged
surgeons to find more minimally invasive techniques for
colorectal cancer. Recently, many of these efforts have
focused on single-incision laparoscopic surgery (SILS).
SILS is performed entirely through one extraction site,
typically through the umbilicus, an embryological nat-
ural orifice that can conceal a surgical scar [10]. Since it
was first reported in 2008, several retrospective studies
have suggested that SILS offers potential benefits over
CLS for the treatment of colorectal cancer, including a
reduced risk of trocar-related complications, reduced
postoperative pain, improved convalescence, and im-
proved cosmetic results [10–14]. However, despite its
encouraging results, SILS is technically challenging be-
cause of the associated limited instrument movement,
loss of triangulation, and in-line viewing, and these tech-
nical difficulties may lead to prolonged operation time,
increased complications, and uncertain oncological out-
comes [12, 14–16]. In addition, in the view of Hamabe
et al., the technical difficulties of SILS were more evident
in cases of sigmoid and rectal cancer, especially when
rectal transection and double-stapling anastomosis were
performed intracorporeally through the umbilical inci-
sion [16]. To minimize the abdominal trauma and the
technical difficulties, the use of single-incision plus one
port laparoscopic surgery (SILS plus one), which in-
cludes an additional port in the right lower quadrant to
SILS for sigmoid and rectal cancer, has gained increasing
attention from colorectal surgeons [16, 17]. Adding a
port in the right lower quadrant can overcome the tech-
nical difficulties and is also convenient for drainage,
which makes it possible to effectively evaluate and con-
servatively manage bleeding, anastomotic leakage, and
chyle leakage [16, 17].
Many studies have reported that SILS plus one is
feasible for colorectal cancer treatment and offers
short-term safety comparable to that of CLS [15, 17].
However, the published studies had several limitations,
such as a retrospective design, small samples, and
poor methodologically quality [15, 17]. There is still
no available evidence from large-scale, randomized
controlled trials assessing the feasibility, short-term
safety, long-term oncological safety, and potential ben-
efits of SILS compared with CLS for rectosigmoid
cancer.
Objective and hypothesis
The objective of this trial is to evaluate the feasibility,
short-term safety, long-term oncological safety, and po-
tential benefits of SILS plus one compared with CLS for
the radical resection of rectosigmoid cancer in a ran-
domized controlled trial. The hypothesis is that SILS
plus one is feasible for the radical resection of rectosig-
moid cancer and offers short-term safety and long-term
oncological safety comparable to that of CLS. In
addition, SILS plus one provides better cosmetic results
and faster convalescence compared with CLS.
Methods/Design
Setting
This is a single-center, open-label, noninferiority, ran-
domized controlled trial. The trial is being undertaken
at Nanfang Hospital of Southern Medical University,
Guangzhou, Guangdong, China, which performs 450
colorectal cancer resections per year. Recruitment
began on April 16, 2014, and the trial is expected to
proceed for 96 months.
Participants
Patients aged 18 to 80 years with rectosigmoid cancer
diagnosed as cT1-4aN0-2 M0 lesions via abdominal
computed tomography (CT) and colonoscopy according
to the 7th Edition of the American Joint Committee on
Cancer (AJCC) Cancer Staging Manual [18] and a tumor
size no larger than 5 cm will be further screened for in-
clusion (Table 1) by a designated investigator.
Recruitment and trial timeline
After being screened for inclusion and exclusion criteria,
the potential participants will be verbally introduced to
the study by an investigator. A signed written informed
consent will be obtained from each patient before his or
her inclusion in the study. A copy of the signed consent
will be given to the participant, and the original consent
will be kept in the hospital. Surgery will be performed
within 7 days of patient enrollment or, if it is not, the
reason will be recorded in the case report form (CRF).
After enrollment, the baseline demographic and clinical
characteristics of the participant will be measured pre-
operatively (Table 2), and any participants who meet the
withdrawal criteria (Table 1) will be withdrawn from the
trial. The flow of participants and time schedule are pre-
sented in Fig. 1.
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From January 2012 to December 2013, 145 patients at
Nanfang Hospital met the inclusion criteria. Based on
our experiences during our single-incision laparoscopic
appendectomy study, we expect a recruitment rate of 90
to 100 % [19]. No provisions or financial compensation
will be offered as recruitment strategies. We expect to
recruit 198 patients within 36 months, and the trial is
designed to proceed for 96 months.
Randomization, allocation concealment, and blinding
The participants will be randomized at 1:1 ratio to re-
ceive either SILS plus one or CLS. A simple random al-
location sequence will be computer generated using
SPSS version 13.0 (SPSS, Inc., Chicago, IL, USA) by a
third party. A nurse will give the surgeon the patient’s
random number and group assignment in an identical,
opaque, sealed envelope the day before surgery. The op-
eration data will be recorded, and the abdominal incision
will be photographed by an investigator who will not be
involved further in the trial. An investigator who is not
involved with the surgery group will perform the
macroscopic examination and photograph the dis-
sected, unfixed specimen. Detailed macroscopic and
microscopic examinations of the dissected fixed speci-
mens according to the AJCC guidelines will be per-
formed by a pathologist who is blind to the patient’s
treatment assignment [18]. An independent investiga-
tor with extensive colorectal experience who is aware
of the participant’s assignment will be responsible for
assessing early morbidity. An investigator will be in
charge of changing the wound dressing but will not
be involved further in the trial. This investigator will
report any cases of wound complications to the morbidity
assessor. The patients’ study-related visits to the hospital
will be conducted by an investigator who is blind to
participant assignment. All of the investigators will be un-
blinded at the patient’s discharge. The statistician will be
blind to participant assignment.
Interventions
Surgery will be performed by investigators with ≥ 100
successful laparoscopic colorectal resections and ≥ 10
transumbilical SILS plus one colorectal resections.
Experimental intervention
After general anesthesia, the patient will be placed in a
lithotomy position on the table. The positions of the
surgeon, assistant, and camera operator are depicted in
Fig. 2a.
An initial 5-cm periumbilical transverse incision will
be made. Then, the homemade multichannel device,
comprising a soft tissue retractor and a surgical glove,
will be placed at the umbilical incision (Fig. 2b). Two
12-mm trocars and one 5-mm trocar will be inserted
through the glove fingers as the observation port for a
10-mm 30° laparoscope, the surgeon’s nondominant op-
eration channel, and the assistant’s operation channel,
respectively. A pneumoperitoneum of 12-13 mmHg will
be established and maintained. One 12-mm trocar will
be placed in the right lower quadrant under laparoscopic
view as the surgeon’s dominant operation channel
(Fig. 3a,b).
Table 1 Inclusion, exclusion, and withdrawal criteria
Inclusion criteria Exclusion criteria Withdrawal criteria
• 18 years < age < 80 years • BMI > 30 kg/m2 • Invasion of adjacent structures
or distant metastasis
• Tumor located in the rectosigmoid (defined as 10 to
30 cm from the anal verge, measured via colonoscopy
or EUS)
• Pregnant or lactating women • Inability to undergo surgery
or anesthesia because of a
changing illness state
• Pathological rectosigmoid cancer • Severe mental disease • Changing illness state requires
an emergency operation
• Clinically diagnosed cT1-4aN0-2 M0 lesions according
to the 7th Edition of the AJCC Cancer Staging Manual
(measured using abdominal CT and colonoscopy or EUS)
• Previous abdominal surgery (except extraperitoneal
surgery)
• Intraoperative colon irrigation
• Tumor size of 5 cm or less • Emergency operation to treat complications
(bleeding, perforation, or obstruction) caused
by colorectal cancer
• Serious protocol violations
• ECOG performance status of 0 to 1 • Need for simultaneous surgery for another disease • Patient required to withdraw
• ASA classification I to III • Malignant disease within the previous 5 years
(except superficial squamous or basal cell cancer
of the skin or in situ cancer of the cervix)
• Informed consent • Nonspeaker of Chinese or English
EUS endoscopic ultrasonography, AJCC American Joint Committee on Cancer, CT computed tomography, ECOG Eastern Cooperative Oncology Group, ASA
American Society of Anesthesiologists, BMI body mass index
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Table 2 Preoperative and postoperative outcome parameters and schedule of study visits and follow-up
Measures Preoperative Daily in-hospital study visits Follow-up
POD 0b POD 1 POD 2 POD 3 POD 4 POD 5 POD ≥6 M1 M3 M6 M9 M12 M15 M18 M21 M24 M30 M36 M42 M48 M54 M60
Inflammatory parameters
(WBC, NE %, CRP, IL-6, TNF-α)
Xa Xc Xc Xc
VAS score X X X X
Short-term recoveryd X X X X X X
Post-voiding residual urine Xa X
EORTC QLQ-C30 Xa X X X
EORTC QLQ-CR29 Xa X X X
IPSS Xa X X X
BIQ X X X
Abdominal incision
photograph
X X X X
Physical examination Xa X X X X X X X X X X X X X X X
CEA, CA72-4, CA19-9 X X X X X X X X X X X X X X X
Chest radiography X X X X X X X X X X X X X X X
Liver ultrasonography X X X X X X X
Abdominal and pelvic
CT scan
X X X X X X X X
Colonoscopy or EUS X X X X X X X X
Adverse event X X X X X X X X X X X X X X X X X X X X X X
aPreoperative study visits will be scheduled within 7 days before surgery; bThe study visit on POD 0 will be scheduled during and after surgery; cInflammatory parameters will be measured at postoperative 4 hours,
24 hours, and 96 hours after skin suture; dShort-term recovery, including time to first flatus, time to resuming liquid diet and soft diet, time to ambulating independently and discharge. POD, postoperative day; M,
month; WBC, white blood cells; NE %, neutrophil percentage; CRP, C-reactive protein; IL-6, interleukin-6; TNF-α, tumor necrosis factor-α; VAS, visual analogue scale; QLQ-C30, Quality of Life Questionnaire-Core 30;
QLQ-CR29, Quality of Life Questionnaire-Colorectal 29; IPSS, International Prostatic Symptom Score; BIQ, Body Image Questionnaire; CEA, carcinoembryonic antigen; CA 72-4, carbohydrate antigen 72-4; CA 19-9,










After the abdomen is explored with the laparoscope,
the patient will be placed in the Trendelenburg position
with the left side elevated 20 to 30°. High ligation of the
inferior mesenteric artery approximately 4 cm above the
abdominal aortic bifurcation will be performed with a
clip for D3 lymphadenectomy (Fig. 3c). Subsequently,
the inferior mesenteric vein will be ligated near the duo-
denojejunal peritoneal fold (Fig. 3c). Then, the medial-
to-lateral dissection will be performed. The distal rectum
will be dissected by inserting a linear stapling device
through the surgeon’s dominant operation channel
(Fig. 3d). The surgical specimens will be removed
through the umbilical incision under the soft tissue re-
tractor and dissected extracorporeally. Intracorporeal
end-to-end anastomosis will be performed using a
circular stapler inserted through the anus and tested
with air insufflation. A drainage tube will be placed in
the pelvic cavity through the surgeon’s dominant operation
channel. The fascia and the skin will be reapproximated
with simple interrupted absorbable and nonabsorbable
Fig. 1 Time schedule and flow of participants
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sutures, respectively. Then, the incision length will be
measured, and the wound will be dressed. Additional
movie files show the operation procedure in more de-
tail (see Additional file 1).
Control intervention
After general anesthesia, the position of the patient, the
surgeon, the assistant and the camera operator will be the
same as described for the experimental group (Fig. 2a).
A periumbilical incision for a 12-mm trocar will be
made as the observation port for a 10-mm 30° laparo-
scope. After a 12- to 13-mmHg carbon dioxide pneumo-
peritoneum is created, additional transabdominal trocars
will be placed under laparoscopic view: one 12-mm tro-
car in the right lower quadrant as the surgeon’s domin-
ant operation channel, one 5-mm trocar in the left
quadrant as the assistant’s nondominant operation
channel, and two 5-mm trocars in the right and left
upper quadrants as the surgeon’s nondominant and
the assistant’s dominant operation channel, respect-
ively (Fig. 4a,b).
After laparoscopic exploration of the abdomen, the
surgical procedure will be performed in the same man-
ner described for the experimental group (Fig. 4c,d).
After distal rectal colon dissection, an extension incision
will be performed, and the rectosigmoid colon will be
Fig. 2 Operative position and single-incision multichannel device. a The patient is placed in a lithotomy position. The surgeon stands at the
patient’s right side with the first assistant at the left side, while the camera operator stands beside the patient’s right shoulder with the monitor
placed beside the patient’s left leg. b The homemade multichannel device comprises a soft tissue retractor and a surgical glove
Fig. 3 Trocar positions and surgical procedure for the experimental intervention group. a, b Trocars and instrument positions for single incision
plus one port laparoscopic surgery (SILS plus one). c Ligation of the inferior mesenteric artery and vein. d The distal rectum is dissected by
inserting a linear stapling device through the surgeon’s dominant operation channel
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extracted under a soft tissue retractor and dissected ex-
tracorporeally. The procedure that follows will be the
same as that described for the experimental group:
1. Mobilization of the splenic flexure will not be
performed routinely except in cases of a lack of
redundancy of the sigmoid colon [14, 20].
2. In the CLS group, the length and the location of the
extension incision will be determined by the
surgeon.
3. Adding ports or converting to open surgery will
be allowed at the surgeon’s discretion if technical
difficulties, the patient’s safety, simultaneous surgery,
or unexpected conditions requiring conversion.
4. Only standard straight laparoscopic instruments
will be used for the operation.
5. A temporary protective loop ileostomy will be
allowed for high-risk patients, such as those taking
steroid medication, those with an abscess discovered
during surgery, or those with a poor nutritional
state [21], at the surgeon’s discretion.
6. The operation procedures for both intervention
groups will be digitally recorded and left unedited.
7. Immediately after the operation, an investigator
will check the macroscopic quality of the
complete mesocolic excision [22] (Fig. 5a) and
measure the length of the proximal and distal
dissection margins (Fig. 5b) and the tumor
diameter (Fig. 5c).
Perioperative management, discharge, and follow-up
Nutritional support will be performed according to Nu-
tritional Risk Screening 2002 [23] and ERAS Society
recommendations [24]. Polyethylene glycol electrolyte
solution (2.5 L) will be administered the day before sur-
gery for bowel preparation. A single short dose of
prophylactic antibiotics (second-generation cephalospo-
rins) will be given intravenously 30 minutes before
surgery [24]. Systemic prophylactic antibiotics (second-
generation cephalosporins) will also be given intraven-
ously within 72 hours postoperatively. Nasogastric tubes
will not be routinely used [24]. Postoperative patient-
controlled opioid-based intravenous analgesia will be
routinely administered directly after surgery in the re-
covery room and discontinued on postoperative day
(POD) 2 [25]. Additional analgesics will be allowed in
cases of breakthrough pain as recommended by the
World Health Organization Analgesic Ladder and at the
discretion of the treating ward physician [26]. The pa-
tient’s urinary catheter will be removed on POD 3. After
the first spontaneous voiding, a bladder ultrasound will
be performed to measure the post-voiding residual urine.
If the patient has symptoms of urinary retention or is
unable to pass urine spontaneously 6 hours after
Fig. 4 Trocar positions and surgical procedure for the control intervention group. a, b Trocars and instrument positions for conventional
laparoscopic surgery (CLS). c Ligation of the inferior mesenteric artery and vein. d The distal rectum is dissected by inserting a linear stapling
device through the surgeon’s dominant operation channel
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catheter removal, a catheter will be reinserted for at least
24 hours [27]. The drain will be removed at the sur-
geon’s discretion and based on the amount of drainage
and the properties of the drained fluid. Participants will
be discharged once they are able to tolerate a soft diet
and ambulate independently (defined as being able to
walk a predefined distance or go to the bathroom inde-
pendently [28]).
Postoperative adjuvant chemotherapy will be per-
formed according to the NCCN guideline [29, 30] at the
surgeon’s discretion and if the participant is willing. Each
participant will be followed up at 1 and 3 months after
surgery, then every 3 months for the first 2 years and
every 6 months for the next 3 years. Quality of life will
be measured with the European Organization for Re-
search and Treatment of Cancer (EORTC) Quality of Life
Questionnaire-Core 30 (QLQ-C30) [31], the EORTC
Quality of Life Questionnaire-Colorectal 29(QLQ-CR29)
[32], and the International Prostate Symptom Score (IPSS)
[33] preoperatively and 1 month, 3 months, and 6 months
postoperatively. The participants will be evaluated for
tumor recurrence using the following methods: physical
examination, carcinoembryonic antigen (CEA), carbohy-
drate antigen 72-4 (CA 72-4), and carbohydrate antigen
19-9 (CA 19-9). Chest radiographs will be obtained every
three months for the first 2 years and then every 6 months
for the next 3 years. Liver ultrasonography will be per-
formed for the first time at the third postoperative month,
then every 6 months for the first 2 years and annually for
the next 3 years. Colonoscopy or EUS and abdominal and
pelvic CT scans will be performed every 6 months for the
first 2 years and then annually for the next 3 years. If the
participant fails to return for follow-up visits, he or she
will be contacted by phone or email to complete the
follow-up data.
Risk-benefit ratio
The potential benefits of SILS compared with CLS are
expected to be fewer trocar-related complications,
reduced postoperative pain, faster convalescence, and
improved cosmetic results [10–14]. The potential risks
of SILS compared with CLS for colorectal cancer treat-
ment are prolonged operation time, increased complica-
tions, and uncertain oncological outcomes. However,
several retrospective studies have reported that the oper-
ation time, complications, pathologic outcomes, and 3-
to 5-year DFS and OS for SILS were comparable to
those of CLS for colorectal cancer [1, 14, 34, 35].
Outcome measures
Primary endpoints
The primary outcome is early morbidity, which will be
divided into morbidity observed during operation and
morbidity observed within 30 days after surgery. Early
morbidity will be assessed on POD 30 and classified ac-
cording to the Clavien-Dindo classification [36].
Secondary endpoints
Secondary endpoints will be measured intraoperatively,
at daily study visits, and at 1, 3, 6, 36, and 60 months
postoperatively. Operative outcomes include operation
time, estimated blood loss during operation, and incision
length. Pathological outcomes compromise tumor size,
length of proximal and distal resection margins, and
number of harvested lymph nodes and will be determined
postoperatively by pathological examination. Postoperative
inflammation and immune response (white blood cells
[WBC], neutrophil percentage [NE %], C-reactive protein
[CRP], interleukin-6 [IL-6], and tumor necrosis factor-α
[TNF-α]) will be measured at 4 hours, 24 hours, and
96 hours postoperatively. Postoperative recovery (time to
first ambulation, flatus, liquid diet, soft diet and duration
of hospital stay) will be measured daily in-hospital and de-
termined using participant self-report. Pain intensity will
be measured using a horizontal visual analogue scale
(VAS; a 0 to 10 cm scale with 0 at the left edge represent-
ing no wound pain, and 10 at the right edge representing
wound pain as bad as it could possibly be) [37] at rest on
Fig. 5 Specimen measurement. a Macroscopic quality of the complete mesocolic excision. b Length of the proximal and distal dissection
margins. c Tumor diameter
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POD 1, 2, 3, and 5. Additional postoperative analgesic use
will be recorded in the CRF. Body image and cosmesis will
be measured using the Body Image Questionnaire (BIQ)
[38] at 1, 3, and 6 months postoperatively. The 3-year
disease-free survival (DFS) and 5-year overall survival
(OS) will be measured at 36 and 60 months postopera-
tively. Confirmation of recurrence will require either the
detection of radiologically apparent lesions that increase
in size over time or a pathology evaluation. The DFS will
be calculated from the time of randomization to the time
of either local or distant progression or death (from any
cause and in the absence of evidence of recurrence) in
participants who have undergone curative surgery. The
OS will be calculated from the time of randomization to
the time of death from any cause. All measurements and
time points are listed in Table 2.
Data management
Data will be recorded in the CRF by an investigator and
reviewed by another investigator for completeness before
it is transferred into the trial database. Any missing data
will be identified and drawn from source data or from
the participants. The CRF will then be transferred into
the trial database and double-checked to ensure accurate
transfer. Each participant will be given an allocation
number according to their randomization. To maintain
participant confidentiality, all data will be identified by
allocation number, and only the investigators will be able
to link the allocation number to the participant’s identi-
fication using a list saved separately from the database.
All study-related participant information will be stored
in a specified investigator’s office in locked filing cabi-
nets. The trial database, photographs and videos will be
double saved. In case of withdrawal, follow-up and data
collection will continue with the participant’s permis-
sion. An investigator will review the database to ensure
accurate data collection using descriptive statistics to
check for missing data and out-of range values. Any un-
clear data will be traced to the original medical records.
Upon the completion of the trial, all study-related data
and trial documents will be archived securely and
retained for a minimum of 10 years at Nanfang Hospital.
Safety and reporting of serious adverse events
All adverse events (AEs, defined according to the Com-
mon Terminology Criteria for Adverse Events (CTCAE)
version 4.0 [39] and the Accordion Severity Grading
System (TASGS) [40]), will be evaluated for severity and
causality. Severity will be graded according to the
CTCAE [39] and TASGS [40]. Causality will be graded
as none, unlikely, possibly, probably, and definitely re-
lated to the intervention. Expectedness will be used to
evaluate the AEs. Any serious adverse events (SAEs, de-
fined according to the International Conference on
Harmonisation (ICH) GCP E6 guidelines [41], TASGS
[40], and CTCAE [39]) will be reported to the chief
investigator (CI) within 24 h of being noted. If the CI
considers an SAE unexpected and related to the study
intervention, he will report it to the Medical Ethics
Committee (MEC) within 72 h of being notified, and a
detailed medical report will be needed within 15 days.
The study’s steering committee, which is organized by
the authors of the protocol and the Department of Gen-
eral Surgery, Nanfang Hospital, will be responsible for
overseeing the study’s progress and safety and will meet
to evaluate morbidity and AEs at least three times: after
the randomization of 25 %, 50 %, and 75 % of the partic-
ipants. If the number of treatments related to SAE oc-
currence is more than 3 % (n = 2) of the sample size in
each group, patient enrollment will be terminated imme-
diately, and the MEC will reassess the safety of the trial.
Statistical methods
Sample size
The sample size was determined for the primary end-
point: early morbidity measured on POD 30. Based on
our database, the early morbidity rate of CLS for colo-
rectal cancer is 15.2 %; for SILS plus one for colorectal
cancer, the early morbidity rate is 11.1 %. The sample
size was determined according to the following:
1. Hypothesis: the early morbidity of SILS plus one is
not higher than that of CLS (noninferiority analysis).
2. We set the noninferiority margin at 10 %.
3. A one-sided analysis with a type I error (α) of 2.5 %
and a power (1-β) of 0.80 was assumed.
Based on these assumptions, a sample size of 90 par-
ticipants per arm was calculated using the NCSS-PASS
(11th edition, NCSS, LLC, Utah, USA). Assuming a
drop-out rate of 10 %, the total number of participants
needed per arm is 99, resulting in a total of 198 partici-
pants for the primary aim.
Statistical analysis
The statistical analysis will be performed using SPSS
version 13.0 (SPSS, Inc., Chicago, IL, USA). A two-sided
p < 0.05 will be considered significant. Descriptive statis-
tics will be used for baseline characteristics. For categor-
ical variables, including the primary outcome, a χ2 test
or Fisher’s exact test will be applied. For continuous var-
iables, Student’s t test or the Mann-Whitney U-test will
be applied. Kaplan-Meier curves and the log-rank test
will be used to analyze the OS and DFS differences
between the two groups. We do not plan to perform
interim analyses. Missing values will not be imputed.
Any outcomes of interest analysis will be performed
based on the intention-to-treat population and per-
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protocol population (PPP), and a standard sensitivity
analysis will be performed based on the PPP.
Ethical considerations
The study will be performed according to the Declar-
ation of Helsinki [42] and the ICH GCP E6 guidelines
[41]. The Medical Ethics Committee of Nanfang Hos-
pital reviewed and approved this study on March 19,
2014 (reference number: NFEC-2014-026). The Medical
Ethics Committee of Nanfang Hospital will be informed
of significant protocol amendments.
Only the patients who signed the informed consent
will be included in the study. The participants will be
informed that the participation in the trial is voluntary
and that they can withdraw consent at any time without
giving reasons.
Dissemination policy
This trial is intended for publication in international
peer-reviewed journals. The results of this study will also
be presented at internationally relevant scientific meet-
ings. The progress and the results of the study will be
saved at Clinicaltrials.gov to allow general access to doc-
umented findings.
Registration
This trial was registered with ClinicalTrials.gov
(https://www.clinicaltrials.gov/ct2/show/NCT02117557?
term=single&cond=colon+cancer&cntry1=ES%3ACN&
rank=11) under the registration number NCT02117557
on April 16, 2014.
Protocol version
This manuscript refers to the second version of the full
study protocol issued on 20 December 2013. Protocol
modifications will be reported to all investigators, the
MEC, all trial participants, and the journal.
Discussion
Although the SILS plus one technique has been adopted
in clinical use because it provides most of the benefits of
SILS and CLS and minimizes the risks associated with
SILS [15, 17], as far as we know, there are only two
large-scale randomized controlled trials with more than
100 samples comparing SILS with CLS for colorectal
cancer treatment. One is the SILVERMAN1 trial for
right colonic cancer [43], and the other is the Multicen-
ter Single-Port Colectomy trial for colon adenocarcin-
oma excluding distal transverse colon cancer, splenic
flexure colon cancer, and descending colon cancer [44].
There are no published results. To the best of our know-
ledge, no large-scale RCT has focused on the risks and
benefits of SILS plus one compared with CLS for recto-
sigmoid cancer treatment.
Early morbidity was chosen as a primary endpoint of
this trial because early morbidity is an indication of
short-term safety, which is a prerequisite for the general
clinical application of a new surgical technique [14].
Moreover, early morbidity is a measure of surgical recov-
ery for patients undergoing major abdominal surgery
[28]. Among all types of early morbidities, we will focus
on intra-abdominal morbidity and trocar-related morbid-
ity, including intraoperative morbidity (such as injuries
and bleeding during surgery) and 30-day postoperative
morbidity (such as anastomotic leakage, anastomotic
bleeding, intro-abdominal bleeding, incision complica-
tions and trocar-related complications). If the morbidity
differs between SILS plus and CLS for rectosigmoid can-
cer, the technical difficulties (such as limited instrument
movement, loss of triangulation, difficulty with rectal tran-
section and intracorporeal double-stapling of anasto-
moses) and the different trocar numbers may be the main
reasons. Moreover, the operation time and estimated
blood loss during surgery have also been used to evaluate
the safety of surgical techniques.
Oncological safety is an important measurement for a
new surgical technique in the field of radical cancer re-
section, and the most powerful evidence of oncological
safety is the long-term DFS and OS. In 2014, a case-
match study compared 27 SILS patients with 27 CLS pa-
tients treated for colorectal cancer, and the 5-year local
recurrence rate was 3.7 % versus 0 (p = 0.55), the distant
metastasis rate was 14.8 % versus 3.7 % (p = 0.15), and
the OS was 92.6 % versus 96.3 % (p = 0.66) for SILS and
CLS, respectively [35]. In the same year, in a propensity-
score matching analysis, Kim et al. compared SILS (n =
60) with CLS (n = 120) for sigmoid cancer. The 3-year
DFS was 89.5 % and 87.4 % (p = 0.751), and the OS was
94.5 % and 97.1 % (p = 0.223) for SILS and CLS, respect-
ively [14]. As the cases and follow-ups accumulated, Yun
et al. recently reported that SILS (n = 239) colorectomy
showed an equivalent of 48 months DFS (89.8 % versus
89.9 %, p = 0.548) and OS (98.7 % versus 98.6 %, p =
0.971) compared with CLS (n = 239) for colon cancer
[1]. Although these three studies suggest that the onco-
logical safety of SILS is comparable to that of CLS for
colorectal cancer, the retrospective design, small samples
and poor methodological quality of these studies might
have resulted in selection bias and evaluation bias, which
would largely reduce the believability of the study re-
sults. Considering all of the above reasons, it is necessary
to evaluate the oncological safety of SILS plus one for
rectosigmoid cancer using the 3-year DFS and the 5-year
OS. Evaluating the long-term DFS and OS of patients
with colorectal cancer requires long-term follow-up;
consequently, the assessment of the pathological out-
comes (such as the tumor size, length of the proximal and
distal resection margins, and the number of harvested
Wang et al. Trials  (2015) 16:539 Page 10 of 13
lymph nodes removed) of each specimen is essential for
predicting oncological safety.
As an essential principle of enhanced recovery, minim-
ally invasive surgery has been championed by a growing
number of surgeons [24]. It seems obvious that the SILS
plus one technique will enhance recovery compared with
CLS by reducing abdominal trauma; however, as the evi-
dence accumulated, there were arguments over whether
the reduction of trocar incision is enough to enhance pa-
tients’ recovery [1, 13, 14, 34, 45]. To settle the argu-
ments, we will use pain intensity, duration of hospital
stay, time to first ambulation, bowel function (time to
first flatus), eating habits (time to resuming liquid diet
and soft diet) and inflammatory and immune responses
(WBC, NE %, CRP, IL-6 and TNF-α) to evaluate pa-
tients’ recovery after abdominal surgery [28]. Among the
above-mentioned measurements, pain is the most com-
monly reported symptom and the most subjective one
[28]. To transform subjective pain into an objective
score, we will use the VAS scale, which is the most sensi-
tive pain scale; compared with the Numerical Rating
Scale and the Four-point Verbal Rating Scale, it can dis-
criminate between small changes in pain intensity [46].
We decided to measure patient pain intensity at rest
because doing so may eliminate the effect of different
levels of mobility on pain intensity. Additionally, we will
record the use of additional postoperative analgesics for
breakthrough pain, which will influence pain intensity,
for further analysis.
The cosmetic advantage of SILS plus one over CLS
seems obvious, and it seems to be a permanent advan-
tage of SILS plus one. However, at present, no study
available assesses whether reducing the use of abdominal
trocars will affect body image, cosmesis, and patient self-
confidence. We will use the BIQ to evaluate the patient’s
subjective feelings about the cosmesis, and we will use
photographs of the incision and the length of incision to
supplement the cosmesis evaluation [38].
This trial has potential limitations. 1) The trial will
take place in only one center, which may impact partici-
pant recruitment or limit the generalizability of the re-
sults to other hospitals. 2) The surgeons, participants,
and investigators who record the surgical information,
photograph the incisions, change the wound dressings,
and perform the study visit after each participant’s dis-
charge will be aware of the group assignment, which
may cause biased estimates of the treatment effect. How-
ever, because of the special nature of nonpharmacologic
trials, it is impossible to blind the surgeon [47]. Al-
though in this trial, the surgeons, the investigators men-
tioned above, and the participants are not blinded, the
pathologists, statistician, and investigators who evaluate
the unfixed specimens and perform the study visits dur-
ing the patients’ hospital stays will be blinded to the
group assignment. Moreover, the participants, surgeons,
and investigators will not be allowed to reveal the group
assignments to the others. These rules can reduce the
treatment effect estimation bias.
Despite its increasing clinical application, the risks and
benefits of SILS plus one for rectosigmoid cancer remain
unclear. This trial is the first study to compare SILS plus
one with CLS for the radical resection of rectosigmoid
cancer in a large-scale, randomized, controlled trial set-
ting. The results of this trial will provide valuable clinical
evidence for the objective assessment of the feasibility,
short-term safety, long-term oncological safety, and po-
tential benefits of SILS plus one compared with CLS for
the radical resection of rectosigmoid cancer.
Trial status
The trial recruitment started in April 2014. As of
June 18, 2015, 82 patients have been registered and
randomized.
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